Tom Clonan (Independent)
Link to this: Individually | In context

Something struck me from what I heard, and I apologise again as I was at the disability matters committee meeting. I suppose it goes with the title “pharmacoeconomic review”, but Professor Barry talked about a cost–benefit analysis. Does he believe that is an ethical way to assess the funding, approval or otherwise of drugs?